Cleveland Clinic | Strategic Alliance Partners
Cleveland Clinic is a nonprofit, multispecialty academic medical center integrating outpatient and hospital care with research and education for better patient outcomes and experience. More than 4,500 staff physicians and researchers provide services through 20 patient-centered institutes. Cleveland Clinic is a 6,500-bed healthcare system with a main campus in Cleveland, 22 hospitals and over 220 outpatient locations. The health system includes five hospitals in Southeast Florida with more than 1,000 beds, a medical center for brain health in Las Vegas, a sports and executive health center in Toronto, and a 364-bed hospital in Abu Dhabi. Cleveland Clinic London, a 184-bed hospital, opened in March 2022. Cleveland Clinic is currently ranked as one of the nation’s top hospitals by U.S. News & World Report.
Latest from Cleveland Clinic
Using Initial Cognitive Symptoms to Predict Trajectories of Neurodegenerative Pathologies
August 6th 2022Jagan A. Pillai, MD, PhD, neurologist, Cleveland Clinic Lou Ruvo Center for Brain Health, discussed a recent study which found faster clinical progression in those with nonamnestic initial cognitive symptoms.
Feasibility and Limitations of Exoskeletons for Multiple Sclerosis Rehab: Francois Bethoux, MD
July 18th 2022The chair of Cleveland Clinic’s Department of Physical Medicine provided background on the usage of exoskeletons in the clinical and at-home settings for rehabbing patients with multiple sclerosis. [WATCH TIME: 2 minutes]
Realistic Expectations and Limitations in MS Rehab With Exoskeletons: Francois Bethoux, MD
July 14th 2022The chair of Cleveland Clinic’s Department of Physical Medicine discussed the different ways a newly approved robotic exoskeleton can improve gait in patients with multiple sclerosis. [WATCH TIME: 4 minutes]
NeuroVoices: Francois Bethoux, MD, on Innovating MS Rehabilitation With the EksoNR Exoskeleton
July 6th 2022The chair of Cleveland Clinic’s Department of Physical Medicine discussed a new rehabilitative approach using a robotic exoskeleton to improve fatigue and gait in patients with multiple sclerosis.
Assessing Early Evidence, Long-Term Potential of EksoRN Robotic Exoskeleton: Francois Bethoux, MD
July 3rd 2022The chair of Cleveland Clinic’s Department of Physical Medicine detailed a pilot study on the rehabilitative impacts of the EksoRN robotic exoskeleton in patients with multiple sclerosis. [WATCH TIME: 5 minutes]
Moderate-to-Severe Post-COVID-19 Sleep Disturbances Common, Especially in Black Individuals
June 8th 2022Patients with moderate-severe compared with normal-to-mild sleep disturbances had worse GAD-2 questionnaire scores, PHQ-2 scores, and PROMIS fatigue scores with no difference in age, sex, or hospitalization due to COVID-19.
Plasma Neurofilament Level Correlated With Symbol Digit Modality Scores Following Ozanimod Treatment
June 1st 2022Both ozanimod doses were associated with greater median reductions in plasma neurofilament light and mean improvements in SDMT score change than interferon beta-1a at month 12 of treatment.
NeuroVoices: Elia Pestana-Knight, MD, on the Importance of Ganaxolone’s Approval in CDD
April 6th 2022The pediatric epileptologist at Cleveland Clinic’s Epilepsy Center discussed data presented at AAN 2022 on the use of ganaxolone in CDD, as well as how its recent approval sets the stage for the future.
Next Steps in Tackling CDKL5 Deficiency Disorder Following First Approval: Elia Pestana-Knight, MD
April 3rd 2022The pediatric epileptologist from Cleveland Clinic provided commentary on the changes needed to improve research and drug development in CDKL5 deficiency disorder, as well as the organizations committed to advancing the state of care. [WATCH TIME: 3 minutes]
Ganaxolone’s Approval Springboards Future CDD Drug Development: Elia Pestana-Knight, MD
April 2nd 2022The pediatric epileptologist at Cleveland Clinic discussed the impact of ganaxolone’s approval for CDKL5 deficiency disorder and how it may create an opportunity for future pipeline agents. [WATCH TIME: 3 minutes]
Assessing, Validating Clinically Relevant Biomarkers for Alzheimer Disease: Jefferson Kinney, PhD
March 15th 2022The founding chair of the department of brain health at the University of Nevada Las Vegas discussed the plethora of Alzheimer disease biomarkers and the need for consensus on the value of each. [WATCH TIME: 3 minutes]
Building Research on Neurodegeneration and Developing Future Researchers: Jefferson Kinney, PhD
March 11th 2022The founding chair of the department of brain health at the University of Nevada Las Vegas provided background on how a newly funded NIH grant will contribute to translational neuroscience research infrastructure. [WATCH TIME: 3 minutes]
Ganaxolone’s Significant Effect on CDKL5 Deficiency Disorder: Elia Pestana-Knight, MD
March 1st 2022The pediatric epileptologist at Cleveland Clinic provided insight on her presentation at the 2022 AAN Annual Meeting that evaluated ganaxolone in phase 3 study of patients with CDKL5 deficiency disorder. [WATCH TIME: 4 minutes]
Gearing Up For the 2022 ACTRIMS Forum: Jeffrey Cohen, MD
February 24th 2022The professor of neurology at Cleveland Clinic and president of ACTRIMS noted his excitement for this year’s Forum, which will feature presentations on a variety of topics in the field of multiple sclerosis. [WATCH TIME: 2 minutes]
Understanding the Precursors of Neurological Brain Diseases and Catching up With Heart Disease
February 19th 2022Imad Najm, MD, provided commentary on the long-term efforts needed to understand the origins of neurological brain diseases and his desire to copy the success of the cardiovascular field.
Outline of New Cleveland Clinic Brain Study: Imad Najm, MD
February 10th 2022The director of Cleveland Clinic’s Epilepsy Center provided insight on a new 20-year initiative to uncover more about the origins of neurological diseases and how they occur prior to symptom onset. [WATCH TIME: 3 minutes]
